Business Wire

EEP-LEGAL

8.1.2021 17:03:29 CET | Business Wire | Press release

Share
EEP Legal Law Firm Announces: EU Corporate Coup: Covert Takeover Creates Dutch Monopoly of Leading Greek Corporations

Netherlands-owned Reggeborgh , has assumed control of 95% of Greek tolls by monopolising multiple Greek markets and defying EU competition regulations. Reggeborgh has acquired minority shares in Gek Terna Group and Ellaktor Group , Greece’s two leading business groups in the Construction, Renewable Energy, and Concessions (Handling, Maintenance and Operation of Toll Motorways). By controlling these companies, Reggeborgh stands to benefit from 32 billion euros of Covid-19 emergency relief funding which is being redirected into the country’s infrastructure, renewables, and construction.

In response, Ellaktor minority shareholder Mr. Michail Koulas has filed a complaint with the European Commission Directorate-General for Competition . According to the Complaint, dated 31.12.2020, Reggeborgh - parent company of Dutch Construction/Real Estate Market Leader VolkerWessels - follows a strategy of monopolization of Greek Construction, Renewable Energy Sources, and the Concession markets. Reggeborgh acquired the majority shares in Gek Terna (31% since March 2019) and Ellaktor (27% since December 2020). Considering low participation levels in both companies' General Assemblies REGGEBORGH now controls their decision making and management. Reggeborgh now has control of more than 95% of the Concessions market (Handling, Maintenance and Operation of Toll Motorways).

Mr. Koulas’s complaint details Reggeborgh's anti-competitive practice of abusing its market dominance to extinguish competition in breach of European Union competition law. Reggeborgh has illegally created a dominant and super-dominant position in segments and subsegments (Markets and Submarkets) crucial for consumer wellbeing and distorts competition in the Greek Geographical Market more widely.

According to Mr Koulas, his intent is:

“To ensure that the concentration at hand is duly examined by the competent competition authorities. Minority shareholders find themselves trapped in a Shareholder Pattern that has not been cleared by competent authorities. Competition and antitrust laws have to be enforced since they are designed to ensure that dominant companies – like the Dutch behemoth REGGEBORGH – are not allowed to foreclose competition illegally. We’re asking the EU to be a neutral party that will examine the facts and enforce the law.”

Ioannis Papanastasopoulos (Attorney at Law, Managing Partner of EEP Legal ) said:

"The case has been referred to the Competent Authorities i.e. Directorate General Competition and we expect its immediate action and scrutiny. The subject under examination is rather sensitive, since 32 billion euros of emergency/relief fund for Covid 19 for Greece will be channeled to Greek infrastructure renewables and construction markets.”

Emmanouil Margomenos (Attorney at Law) senior legal counsel for the team instructed to file the complaint said:

“There are obvious implications involved to the GEK TERNA / ELLAKTOR acquisition and concentration to a single undertaking. Those two market leaders becoming one entity under single control of REGGEBORGH results in REGGEBORGH controlling every single kilometre of toll motorway in Greece.”

The European Commission is already reviewing the complaint and will decide whether to open a formal investigation into Reggeborgh ’s anti-competitive practices.

Ioannis Papanastasopoulos,

EEP LEGAL, MANAGING PARTNER

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release

Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit

Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse

Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release

Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye